본문으로 바로가기 주메뉴 바로가기

사용자별 맞춤메뉴

자주찾는 메뉴

추가하기
닫기

연구성과

contents area

detail content area

Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
  • 작성일2020-02-07
  • 최종수정일2020-02-10
  • 담당부서연구기획과
  • 연락처043-719-8033
  • 875

Nature Communication, 2019. 10(1), 3991-, DOI: https://doi.org/10.1038/s41467-019-11867-6


Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening

Minsuh Kim, Hyemin Mun;Chang Oak Sung;Eun Jeong Cho;Hye-Joon Jeon;Sung-Min Chun;Da Jung Jung;Tae Hoon Shin;Gi Seok Jeong;Dong Kwan Kim;Eun Kyung Choi;Seong-Yun Jeong;Alison M. Taylor;Sejal Jain;Matthew Meyerson;Se Jin Jang


Abstract

    Lung cancer shows substantial genetic and phenotypic heterogeneity across individuals, driving a need for personalised medicine. Here, we report lung cancer organoids and normal bronchial organoids established from patient tissues comprising five histological subtypes of lung cancer and non-neoplastic bronchial mucosa as in vitro models representing individual patient. The lung cancer organoids recapitulate the tissue architecture of the primary lung tumours and maintain the genomic alterations of the original tumours during long-term expansion in vitro. The normal bronchial organoids maintain cellular components of normal bronchial mucosa. Lung cancer organoids respond to drugs based on their genomic alterations: a BRCA2-mutant organoid to olaparib, an EGFR-mutant organoid to erlotinib, and an EGFR-mutant/MET-amplified organoid to crizotinib. Considering the short length of time from organoid establishment to drug testing, our newly developed model may prove useful for predicting patient-specific drug responses through in vitro patient-specific drug trials.



  • 본 연구는 질병관리본부 연구개발과제연구비를 지원받아 수행되었습니다.
  • This research was supported by a fund by Research of Korea Centers for Disease Control and Prevention.


본 공공저작물은 공공누리  출처표시 조건에 따라 이용할 수 있습니다 본 공공저작물은 공공누리 "출처표시" 조건에 따라 이용할 수 있습니다.
TOP